CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an Envelope addressed to: Mail Stop Disclosure Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:

Date: 8/10/2006 By: Winsome A. St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:	)	
Frank Bergmann, et al.	) EXAMINER:	David C. Thomas
SERIAL NO.: 10/540,406	) ART UNIT:	1637
FILED: June 24, 2005	) Confirmation No. 8359	
FOR: METHOD FOR BISULFITE TREATMENT	) DOCKET NO: 21581-US	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Disclosure.
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicant submits herewith a Form-1449, in compliance with the duty of disclosure requirements of 37 C.F.R. §1.56, 1.97 and 1.98, listing accompanying documents that may be considered material to the examination of this application. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits, whichever event occurs last. No certification or fee is therefore required under 37 C.F.R. § 1.97(b). However, should the Commissioner determine that fees are due in order for the Information Disclosure Statement to be considered at this stage, the Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to Deposit Account No. 50-0812.

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested.

Respectfully submitted,

Date: 8/10/06

Charles M. Doyle
Reg. No. 39,175

Correspondence Address:
Roche Molecular Systems, Inc
1145 Atlantic Avenue
Alameda, CA 94501
Tele: (510) 814-2800
Fax: (510) 814-2973

U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. **21581-US**	Serial No. **10/540,406**
LIST OF INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	Applicants: **Frank Bergmann, et al.**	
	Filing Date: **June 24, 2005**	Group: **1637**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	1	4,683,202	07/28/87	Mullis, et al.	435	91	10/25/85
	2	5,130,238	07/14/92	Malek, et al.	435	91	08/23/89
	3	5,137,806	08/11/92	LeMaistre, et al	435	6	12/11/89
	4	5,210,015	05/11/93	Gelfand, et al	435	6	08/06/90
	5	5,234,809	08/10/93	Boom, et al	435	91	07/01/91
	6	5,487,972	01/30/96	Gelfand, et al	435	6	01/05/93
	7	5,552,277	09/03/96	Nelson, et al	435	6	07/19/94
	8	5,595,890	01/21/97	Newton, et al	435	91.2	02/17/95
	9	5,639,611	06/17/97	Wallace, et al	435	6	11/09/94
	10	5,786,146	07/28/98	Herman, et al	435	6	01/03/96
	11	5,804,375	09/08/98	Gelfand, et al	435	6	04/25/95
	12	6,174,670 B1	01/16/01	Wittwer, et al	435	6	06/04/97
	13	6,331,393 B1	12/18/01	Laird, et al	435	6	05/14/99

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	14	0 200 362 B1	12/10/86	EP				
	15	0 201 184 B1	12/17/86	EP				
	16	0 389 063 B1	09/26/90	EP				
	17	0 439 182 B1	07/31/91	EP				
	18	1 394 172 A1	03/03/04	EP				
	19	WO 90/01069	02/08/90	PCT				
	20	WO 92/008800	01/23/92					
	21	WO 92/02638	02/20/92	PCT				
	22	WO 96/41811	12/27/96	PCT				
	23	WO 99/16781	04/08/99	PCT				
	24	WO 99/40098	08/12/99	PCT				
	25	WO 00/32762	06/08/00	PCT				

	26	WO 00/37291	06/29/00	PCT				
	27	WO 01/37291 A1	05/25/01	PCT				
	28	WO 01/98528 A2	12/27/01	PCT				
	29	WO 02/31186 A2	04/18/02	PCT				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	30	Abramson, R., et al., 1993, "Nucleic acid amplification technologies", *Current Opinion in Biotechnology,* 4:41-47
	31	Alderton, R., et al., 1992, "Magnetic Bead Purification of M13 DNA Sequencing Templates", *Analytical Biochemistry,* 201:166-169
	32	Ausubel F., et al., 2001, "Current Protocols In Molecular Biology", *John Wiley & Sons, Inc.,* Supplement 55-56:1-10
	33	Barany, F., 1991, "The Ligase chain Reaction in a PCR World", *PCR Methods and Applications,* 5-16
	34	Barany, F., 1991, "Genetic disease detection and DNA amplification using cloned thermostable ligase", *Proc. Natl. Acad. Sci. USA,* 88:189-193
	35	Benyajati, C., et al., "Alcohol dehydrogenase in Drosophila: isolation and characterization of messenger RNA and eDNA clone", *Nucleic Acids Research,* 8:5649-5667
	36	Clark, S., et al., 1994, "High sensitivity mapping of methylated cytosines", *Nucleic Acids Research,* 22(15):2990-2997
	37	Feil, R., et al., 1994, "Methylation analysis on individual chromosomes: improved protocol for bisulphate genomic sequencing", *Oxford University Press,* 22(4):695-696
	38	Frommer, M., 1992, "A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands", *Proc. Natl. Acad. Sci. USA,* 89:1827-1831
	39	Grigg, G., et al., 1994, "Sequencing 5-Methylcytosine Residues in Genomic DNA", *BioEssays,* 16(6):431436
	40	Grigg, G., 1996, " Sequencing 5-methylcytosine residues by the bisulphate method", *The Journal of Seq.&Mapping* 6:189-198
	41	Grunau, C., et al., 2001, "Bisulfite genomic sequencing: systematic investigation of critical experimental parameters", *Nucleic Acids Research,* 29 (13e65):1-7
	42	Guatelli, J., et al., 1990, "Isothermal, *in vitro* amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication", *Proc. Natl. Acad. Sci. USA,* 87:1874-1878
	43	Hayatsu, H., et al., 1970, "The Addition of Sodium Bisulfite to Uracil and the Cytosine", *Journal of the American Chemical Society,* 92 (3):724-726
	44	Hayatsu, H., et al., 1970, "Reaction of Sodium Bisulfite with Uracil, Cytosine, and their Derivatives", *Biochemisrty* 9 (14): 2858-2864
	45	Komlyama, M., et al., 1994, "Catalysis of Diethylenetriamine for Bisulfite-Induced Deamination of Cytosine in Oligodeoxyribonucleotides", *Tetrahedron Letters,* 35(44):8185-8188
	46	Kubareva, E., et al., 2002, "Determination of Methylation Site of DNA-Methyltransferase *nla*X by a Hybrid Method', *BioTechniques* 33:526-531
	47	Kwoh, D., et al., 1989, "Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format", *Proc. Natl. Acad. Sci. USA,* 86:1173-1177

	48	Oakeley, E., 1999, "DNA methylation analysis: a review of current methodologies", *Pharmacology & Therapeutics,* **84**:389-400
	49	Olek, A., et al., 1996, " A modified and improved method for bisulphate based cytosine methylation analysis", *Nucleic Acids Research,* **24**(24):5064-5066
	50	Paulin, R., et al., 1998, "Urea improves efficiency of bisulphate-mediated sequencing of 5'-methylcytosine in genomic DNA", *Nucleic Acids Research,* **26**(21):5009-5010
	51	Raizis, A., et al., 1995, "A Bisulfite method of 5-Methylcytosine Mapping That Minimizes Template Degradation", *Analytical Biochemistry,* **226**:161-166
	52	Sabban, E., et al., 1982, "The Effect of Bisulfite-induced C→U Transitions on Aminoacylation of *Escherichia coli* Glycine tRNA', *The Journal of Biological Chemistry,* **257** (9) 4796-4805
	53	Slae, S, et al., 1978, "Deamination of Cytidine by Bisulfite: Mechanism at Neutral pH", *J Org Chem.,* **43** (21):497-4200
	54	Whelen, A., et al., 1996, "The Role of Nucleic Acid Amplification and Detection in the Clinical Microbiology Laboratory", *Annu. Rev. Microbid,* **50**:349-379
	55	Wu, D., et al., 1989, "The Ligation Amplification Reaction (LAR) - Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation

EXAMINER6	DATE CONSIDERED

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.